The earnings call reflects a company at a pivotal moment, with significant progress in clinical studies and plans for expansion into multiple high-value indications. While the financials show a decline in revenue and increased expenses, the strategic initiatives and successful capital raising efforts position Theralase for future growth.

Company Guidance

During the call, Theralase Technologies provided guidance on several metrics and strategic initiatives. The company is on track to complete enrollment in its registrational bladder cancer study by summer 2025, with a 15-month patient follow-up expected to conclude by the third quarter of 2026. Theralase plans to file a New Drug Application with Health Canada and the FDA in the fourth quarter of 2026, aiming for marketing approval in early 2027. Financially, the company reported nominal revenues of $91,000 for Q1 2025, largely from its Cool Laser Therapy systems, down from $175,000 the previous year. Despite a net loss of $1.47 million, Theralase has raised nearly $7.5 million over the past 24 months through private placements. The company is exploring a potential U.S. uplist and institutional financing, which could enhance its capital position and broaden its investor base. Additionally, Theralase is advancing a pipeline that includes nine new indications, with plans for Phase I/II clinical studies in 2026. The company highlighted a 62% complete response rate in its bladder cancer study, emphasizing the safety and efficacy of its Ruvidar treatment.

Completion of Bladder Cancer Study Enrollment

Theralase is on track to complete enrollment in a critical bladder cancer study by the summer of 2025, marking a significant milestone in their clinical development.

Expansion into New Oncology and Virology Indications

Theralase plans to expand its pipeline into 9 high-value indications, including brain cancer, lung cancer, pancreatic cancer, and Herpes Simplex virus, positioning the company for growth in these areas.

Strong Interim Clinical Results

Study II for bladder cancer achieved a 62% complete response rate at any time, with no serious adverse events related to the treatment, indicating a promising safety and efficacy profile.

Potential U.S. Listing and Institutional Raise

Theralase is exploring a U.S. institutional raise and listing, which could broaden the investor base, improve stock liquidity, and provide necessary capital for pipeline expansion.

Successful Capital Raising

Theralase successfully closed private placements totaling $730,000 in the first and second quarters of 2025, contributing to nearly $7.5 million raised over the past 24 months.

Theralase Technologies (TSE:TLT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:TLT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 26, 2025	2025 (Q3)	>-0.01 / -	-0.004	―	―	―
Aug 26, 2025	2025 (Q2)	>-0.01 / >-0.01	-0.005	20.00% (<+0.01)	―	―
May 29, 2025	2025 (Q1)	>-0.01 / >-0.01	-0.006	0.00% (0.00)	―	―
Mar 12, 2025	2024 (Q4)	>-0.01 / >-0.01	0	―	―	―
Nov 27, 2024	2024 (Q3)	>-0.01 / >-0.01	0	―	―	―
Aug 12, 2024	2024 (Q2)	>-0.01 / >-0.01	0	―	―	―
May 30, 2024	2024 (Q1)	0.00 / >-0.01	-0.01	40.00% (<+0.01)	―	―
Mar 27, 2024	2023 (Q4)	0.00 / 0.00	0	―	―	―
Nov 29, 2023	2023 (Q3)	-0.01 / 0.00	-0.01	―	―	―
Aug 29, 2023	2023 (Q2)	-0.01 / 0.00	-0.006	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:TLT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 26, 2025	C$0.22	C$0.22	0.00%
May 29, 2025	C$0.21	C$0.20	-4.76%
Mar 12, 2025	C$0.24	C$0.22	-8.33%
Nov 27, 2024	C$0.30	C$0.21	-30.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Theralase Technologies (TSE:TLT) report earnings?

Theralase Technologies (TSE:TLT) is schdueled to report earning on Nov 26, 2025, TBA (Confirmed).

What is Theralase Technologies (TSE:TLT) earnings time?

Theralase Technologies (TSE:TLT) earnings time is at Nov 26, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:TLT EPS forecast?

TSE:TLT EPS forecast for the fiscal quarter 2025 (Q3) is >-0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing